Literature DB >> 24424924

Immunodominant proteins of Borrelia burgdorferi, the etiological agent of lyme borreliosis.

B Wilske1, V Preac-Mursic, R Fuchs, E Soutschek.   

Abstract

Lyme borreliosis, a multisystem disorder involving the skin, the nervous system, the heart, the joints and many other organs, is a worldwide infectious disease which is transmitted by ticks of the Ixodes complex. Most frequently diagnosis is accomplished by detection of antibodies because the Borrelia are difficult to cultivate. Present serodiagnostic methods, however, are impaired by low sensitivity and unspecific reactions. The selection of immunodominant antigens with low cross-reactivity to other bacteria should improve antibody detection. Borrelia burgdorferi proteins have been analysed for cross-reactivity with immune sera from unrelated bacteria, and sera from patients with different stages of the disease. Suitable antigens for improving serodiagnosis have been detected and are reported here. In view of the immunological heterogeneity of Borrelia proteins, sensitivity of antibody detection may possibly be increased by using recombinant antigens derived from different strains. Immunization with recombinant OspA (a flagellum-associated protein) from a North American isolate protected mice from the challenge with three North American isolates. However, for development of an effective vaccine (especially in Europe), the heterogeneity of OspA has to be considered.

Entities:  

Year:  1991        PMID: 24424924     DOI: 10.1007/BF00328982

Source DB:  PubMed          Journal:  World J Microbiol Biotechnol        ISSN: 0959-3993            Impact factor:   3.312


  29 in total

1.  Protection of mice against the Lyme disease agent by immunizing with recombinant OspA.

Authors:  E Fikrig; S W Barthold; F S Kantor; R A Flavell
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

2.  The Borrelia burgdorferi flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene.

Authors:  R Wallich; S E Moter; M M Simon; K Ebnet; A Heiberger; M D Kramer
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Thermoregulation of protein synthesis in Borrelia burgdorferi.

Authors:  R G Cluss; J T Boothby
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

4.  Antigenic variability of Borrelia burgdorferi.

Authors:  B Wilske; V Preac-Mursic; G Schierz; R Kühbeck; A G Barbour; M Kramer
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Serological diagnosis of erythema migrans disease and related disorders.

Authors:  B Wilske; G Schierz; V Preac-Mursic; K Weber; H W Pfister; K Einhäupl
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

6.  The 83-kilodalton antigen of Borrelia burgdorferi which stimulates immunoglobulin M (IgM) and IgG responses in infected hosts is expressed by a chromosomal gene.

Authors:  R B Lefebvre; G C Perng; R C Johnson
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

7.  A specific and sensitive assay for the Lyme disease spirochete Borrelia burgdorferi using the polymerase chain reaction.

Authors:  P A Rosa; T G Schwan
Journal:  J Infect Dis       Date:  1989-12       Impact factor: 5.226

8.  Immunochemical characterization of and isolation of the gene for a Borrelia burgdorferi immunodominant 60-kilodalton antigen common to a wide range of bacteria.

Authors:  K Hansen; J M Bangsborg; H Fjordvang; N S Pedersen; P Hindersson
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

9.  Isolation of antigenic components from the Lyme disease spirochete: their role in early diagnosis.

Authors:  J L Coleman; J L Benach
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

10.  Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis.

Authors:  M Karlsson; K Hovind-Hougen; B Svenungsson; G Stiernstedt
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.